Phase I Trial of Recombinant Human Interleukin 4
Author Information
Author(s): M.H. Gilleece, J.H. Scarffe, A. Ghosh, C.M. Heyworth, E. Bonnem, N. Testa, P. Stern, T.M. Dexter
Primary Institution: Christie Hospital NHS Trust, Manchester
Hypothesis
Can recombinant human interleukin 4 (IL-4) be safely administered to patients with malignancies?
Conclusion
The study found that IL-4 can be administered subcutaneously, but significant toxicity was observed at higher doses without clear evidence of antitumor effects.
Supporting Evidence
- Two patients at the highest dose experienced severe toxicity.
- Patients reported flu-like symptoms and fatigue.
- Modest increases in neutrophil and platelet counts were observed.
Takeaway
Doctors tested a new medicine called IL-4 on nine sick people to see if it was safe, but it made some of them feel really bad.
Methodology
Nine patients received daily subcutaneous injections of IL-4 at varying doses, and their health was monitored for toxicity and biological effects.
Potential Biases
Potential bias due to the small number of participants and lack of a control group.
Limitations
The study had a small sample size and was limited to a Phase I trial focusing on toxicity rather than efficacy.
Participant Demographics
Patients were over 18 years old with confirmed malignancies, mostly solid tumors, and some had previous treatments.
Statistical Information
P-Value
p<0.00005 for neutrophils, p=0.0024 for platelets
Statistical Significance
p<0.00005 for neutrophils, p=0.0024 for platelets
Want to read the original?
Access the complete publication on the publisher's website